{
  "pmcid": "8600451",
  "sha256": "ee28c4f2857d391ce56f528784847f2cc3aa22d74cb7a45af3d32bbf1cdd57f0",
  "timestamp_utc": "2025-11-10T00:10:04.220603+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.644516531503438,
    "reading_ease": 30.99985443959244,
    "word_count": 229
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of Inhaled Epoprostenol vs. Inhaled Nitric Oxide in Lung Transplantation"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This randomised, blinded, parallel-designed equivalence trial involved 201 adult LT patients"
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligibility included adult patients undergoing single or bilateral LT."
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised 1:1 to iNO or iEPO"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was severe/grade 3 primary graft dysfunction (PGD-3) at 24, 48, or 72 hours post-LT."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "randomised 1:1 to iNO or iEPO using computer-generated sequences with allocation concealment."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding encompassed participants, clinicians, data managers, and statisticians."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "201 patients were randomised; 103 to iEPO and 98 to iNO."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "In the intention-to-treat analysis, PGD-3 occurred in 46/103 (44.7%) iEPO and 39/98 (39.8%) iNO"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "PGD-3 occurred in 46/103 (44.7%) iEPO and 39/98 (39.8%) iNO, with a risk difference of 4.9% (TOST 90% CI, â€“6.4% to 16.2%; P = .02 for equivalence)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial Registration: NCT03081052."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Health system-funded."
      }
    },
    "total_score": 24,
    "max_score": 25
  }
}